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Summary. The time course and dose dependency of the incidence of 
bone-sarcomas mong 900 German patients treated with high doses of 
radium-224 is analysed in terms of a proportional hazards model with 
a log-normal dependency of time to tumor and a linear-quadratic dose 
relation. The deduced ose dependency agrees well with a previous analy- 
sis in terms of a non-parametric proportional hazards model, and con- 
firms the temporal distribution which has been used in the Radioepide- 
miological Tables of NIH. However, the linear-quadratic dose-response 
model gives a risk estimate for low doses which is somewhat less than 
half that obtained under the assumption of linearity. 
1. Introduction 
For more than three decades, a follow-up has been conducted of patients 
who were injected with high doses of the short lived e-emitter radium-224 
in several German clinics in the years 1944 to about 1964. This is a group 
of 218 children and juveniles, mostly treated for bone tuberculosis with 
activities up to 5 MBq per kg body weight, and 682 adults treated for anky- 
losing spondylitis or bone tuberculosis or other diseases with, on the average, 
substantially lower activities per body weight. The observations, published 
in a series of earlier eports [6, 7, 8], have become one of the most important 
sources of knowledge on the dose and time dependency of bone sarcomas 
induced by an e-emitter. They continue to provide essential information 
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also on other late effects uch as cataracts, tooth breakages, or severe kidney 
damages [8]. 
The bone sarcomas in the radium-224 patients occurred in a wave which 
reached a maximum about 8 years after treatment and continued, at decreas- 
ing level, to about 30 years [6]. This type of temporal distribution is striking- 
ly similar to that of the leukemias induced in the survivors of the atomic 
bomb explosions in Hiroshima and Nagasaki [3]. 
The dose and time dependencies of radiation induced malignancies are 
critical input information for the establishment of radioepidemiological t - 
bles. The tables established by NIH [9] specify the probabilities of causation 
of various tumors. The only effect of an incorporated e-emitter considered 
in these tables is that of bone sarcomas induced by radium-224; the treat- 
ment is based on the follow-up of the radium-224 patients. In the mathemati- 
cal model a log-normal temporal distribution of the incidence of bone sarco- 
mas after exposure to radium-224 is assumed. The parameters of this distri- 
bution and an assumed linear dose dependency are obtained from simplified 
calculations, with no differentiation between dose classes and with approxi- 
mative corrections for competing risks, i.e. for the disappearance of patients 
from the observation. In a more recent study Land [4] extended this treat- 
ment and has given somewhat modified results, again in terms of a log- 
normal distribution of times to the tumor. He also compared the essential 
results with temporal distributions for other radiation induced tumors. 
A somewhat different approach, in terms of a non-parametric maximum 
likelihood fit to a proportional hazards model [1], was used in an analysis 
of the time and dose distribution of the incidence of bone sarcomas in 
the radium-224 patients. This study was not restricted to the assumption 
of a linear dependency on dose, and the fit of the data to a linear-quadratic 
dose relation resulted in substantially reduced risk estimates at low doses. 
The time dependency appeared to be independent of dose and the age at 
treatment. 
The singular nature of the data and their implications for the probability 
of causation tables make it desirable to combine the treatment in terms 
of the log-normal distribution of times to the tumor with a proportional 
hazards analysis. 
2. Summary of the data 
The follow-up of the radium-224 patients comprises observations on various 
late effects, apart from the bone sarcomas, but only the latter data are 
considered in the present context. The data are summarized in Table 1. 
Additional details are found in several earlier reports [5-8]. The classifica- 
tion in the table follows the one adopted earlier by Spiess and Mays. Among 
900 patients, 38 with unknown doses (among them 6 with bone sarcoma) 
were excluded from the analysis. Of the 48 patients with known doses who 
incurred bone sarcomas, 2 later developed a further bone sarcoma. In both 
cases the pathology indicated that these were no secondary tumors, and 
the two additional cases were, therefore, included in the analysis. The 
105 
• E 
-~ o 
( .4 . -  .,-.4 
U ..~ 
0 
(,0 • 
' -3  
( ] )  . , .~  
>,., 
t- 
o 
4 D . ,_...+ 
o 4_I 
g 
[ J~ .---3 
0 t-  
. , '4  
40 
20 
20 
40 
' ' ' ' ' ' ' 't. . ' . . . .  ' ,+'+ !.; . ' , . '  +.!I : - . .  - '  ' ' ' ' ' 
- : .. . " . c  : :?. ~,~.. ; ,;~ :.7[~i, , .  .~  + ; ,;:~ ':-~v;. ~-+ :..:  ! . ' : . ." ~ • " 
• : ' .': .....!.. : : 15-<";,::'f':: ` )  ~:~:'-~~-.: ":~:7+'(,: +7;"~. '.':"' ' • 
. -. ,,... ~ ?!i,::,.,."~.%.;,"+::~'+;~-¢-.,::~ ,'~~: . . . . '~' . , . ;~+. "~.~,~ :, . • . . . .  
, " " ~ ' -~.-'.'~L'-Y+:. "++~+';i};~:,'~:[;:"..Lg~x-i : .~ . ' i t " '  :.: ~ :" :;: 
i i 1 1 i I I  T I I I I I I I  I 0 I I I I i 
O. i 1 10 100 
meon ske]etol dose (Oy) 
F ig .  1. The  48  pat ients  who incur red  bone  sarcoma are represented by  vert ica l  l ines f rom 
their  age at in ject ion to t ime at tumor  d iagnos is .  The  50 bone  sarcomas  are g iven  by heavy  
dots. The  l ight dots  in the lower  pane l  g ive the d is t r ibut ion o f  ages at in ject ion.  The  pat ients  
w i thout  bone  sarcoma re represented,  in the upper  panel ,  by  a cha in  o f  po ints  f rom year  
at in ject ion to last year  of  fo l low-up,  w i th  one  po in t  on  the average  per 5 years  
decision had, however, no substantial influence on the results; these remain 
essentially unchanged, when the analysis was restricted to first bone tumors 
i.e., when patients were considered at risk only until a bone tumor occurred. 
The individual mean skeletal doses 1 were calculated by Mays on the basis 
of the injected activities, body weights, and ages at treatment of the patients 
[103. 
Figure 1 complements Table 1. It represents the distribution of the pa- 
tients in mean skeletal dose. In the bottom part of the diagram, each patient 
is represented by his age at treatment with a small dot. In the top part 
of the diagram all patients without bone sarcoma are represented by a 
vertical chain of dots, somewhat randomly spaced but with one dot on 
average for 5 years of observation. The patients who developed a bone 
sarcoma are indicated by solid vertical lines. The position of the heavy 
dots, which represent the appearance of bone sarcomas, can be related to 
the density of neighbouring points; this indicates the number of patients 
at risk with similar doses at similar times after treatment. 
In the bottom part of the diagram, one distinguishes readily the group 
of adults with their lower doses from the group of children and juveniles 
with higher doses. In the upper part of the diagram one notes the increasing 
1 In the present  art ic le numer ica l  results are g iven in terms of  the 'mean skeleta l  dose' ,  D s. 
Al ternat ive ly  one  cou ld  use the quant i ty  'endostea l  dose' ,  De, wh ich  is the reference quant i ty  
in the BE IR  report  [23 and  in the Rad ioep idemio log ica l  Tab les  [9 ]  
D e = 7.5  D+ 
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Table 1. Synopsis of data through 1987 
Number of patients included in analysis=832; Number of patients with bone sarcoma=48 
(double: 2); Number of patients excluded from analysis because of missing dose = 38 (6 with 
bone sarcoma); lost to follow up = 30 
Number of Mean age a 
patients with at first at last at bone 
bone injection follow up sarcoma 
sarcoma 
Mean 
skeletal 
dose (Gy)" 
all adults 628 13 38.7 (10.8) 61.8 (11.6) 46.5 (10.9) 2.08 (1.50) 
ankylosingspondylitis 366 5 41.3 (9.5) 63.7 (10.1)58.2 (4.4) 1.43 (1.00) 
tuberculosis 218 8 33.5 (10.6) 58.8 (13.0) 39.1 (6.4) 3.25 (2.22) 
other 44 0 43.1 (12.6) 61.0 (13.5) - (-) 1.73 (1.26) 
male adults 469 11 39.3 (10.2) 62.3 (11.1) 47.6 (11.2) .85 (1.52) 
ankylosingspondylitis 345 5 41.2 (9.4) 63.6 (10.1)58.2 (4.4) 1.42 (1.00) 
tuberculosis 104 6 32.7 (9.7) 58.4 (12.4) 38.8 (6.5) 3.25 (2.03) 
other 20 0 40.5 (10.8) 58.7 (13.6) - (-) 1.93 (1.41) 
female adults 159 2 37.0 (12.4) 60.4 (13.1) 40.0 (6.0) 2.78 (2.23) 
ankylosing spondylitis 21 0 42.5 (10.7) 64.7 (8.5) (8) 1.62 (0.98) 
tuberculosis 114 2 34.2 (11.2) 59.1 (13.5) 40.0 (6.0) 3.25 (2.39) 
other 24 0 45.3 (13.5) 62.9 (13.1) - (-) 1.57 (1.10) 
children andjuveniles 204 35 11.6 (5.3) 38.5 (13.1) 19.7 (5.8) 10.71 (8.82) 
boys 105 16 11.6 (5.3) 39.5 (12.9) 22.2 (6.4) 11.36 (9.61) 
girls 99 19 11.7 (5.3) 37.3 (13.3) 17.7 (4.4) 10.02 (7.84) 
a Mean and (standard eviation) 
frequency of bone sarcomas in the high dose class. One concludes, even 
from this diagram, that there is no appreciable shift in the average time 
to the bone sarcomas with increasing dose. 
3. Summary of results from earlier analyses 
Results from the continuing follow-up of the radium-224 patients were 
reported in a number of earlier articles [6-8]. Some essentials are summa- 
rized in the following. 
Based on national bone-sarcoma rates, the expected number of bone 
sarcomas was, for the follow-up until 1984 only 0.2 [-8]. This number is 
so small, in comparison with the 50 bone sarcomas observed in this group 
of patients, that little error can be introduced by the assumption that all 
of the observed cases were induced by radiation. Of these bone sarcomas 
all but one occurred from 4 to 25 years after the radium-224 treatment. 
The last bone sarcoma occurred recently, 33 years after the radium-224 
injections. Before this observation, it had been believed that the enhanced 
bone-sarcoma r te was mainly extinguished, 25 years after injection. The 
top panel of Fig. 2 gives the distribution, in time after treatment, of the 
absolute numbers of observed bone sarcomas. 
The same panel also contains the number of patients till in the follow-up 
at specified times after treatment. The time of observation is more than 
Fig. 2. In the upper panel the 
numbers of bone sarcomas and 
the numbers of patients till 
under observation are plotted 
versus time after injection. 
The second panel from top gives 
the average of the mean skeletal 
dose in the collective of patients 
still at risk. The shaded area 
represents the standard error. 
The second panel from bottom 
gives the cumulative rate per gray 
that results under the assumption 
of linearity in dose (see (2)). The 
shaded area gives the standard 
deviation. The bottom panel gives 
the rate of bone sarcoma per year 
and per gray that corresponds to 
the cumulative rate in the second 
panel from bottom 
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30 years for most of the surviving patients; for longer observation times 
the data can, therefore, still change. 
3.1 Sum-limit estimate and correction for changes in average dose 
From a competing risk corrected analysis - and under the assumption of 
proportionality of risk and dose - Mays and Spiess concluded that there 
are no substantial differences in the bone-sarcoma rates in the different 
groups of patients [6, 8]. Neither age at injection, nor original illness, nor 
sex appear to influence the rate of radiation induced bone sarcoma per 
unit dose. The data for the various groups of patients were, therefore, pooled, 
and - under the assumption of proportionality of risk and dose - the rate 
of bone sarcomas per unit dose was derived in its dependency on time 
after treatment. 
Two basic quantities need to be defined for an explanation of the compu- 
tations. The (differential) bone-sarcoma r te 2, r(t, D), refers to a patient who 
received the dose D and who is still at risk at time t after the treatment. 
If time is counted in years after treatment, r(t, D) is the conditional probabili- 
z The more technical term 'hazard function' is frequently used for the quantity, r(t, D), and 
the term 'cumulative hazard function' for R(t, D) 
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ty - given survival to that time - that a patient who received the dose 
D, incurs a bone sarcoma in the year t. A related quantity is the cumulative 
rate of bone sarcomas, which equals the integral of the rate, r(t, D), and 
is denoted by R(t, D). It is often practical to refer to the cumulative rate 
because it is less affected by statistical fluctuations. 
If all patients are considered as members of one group without regard 
to their different doses, one can derive the cumulative rate from the sum-limit 
estimate: 
ni 
R(O = Z N (1) 
i<_t 
where ni is the number of bone sarcomas in year i after treatment, and 
N~ is the number of patients till under observation i  this year. 
The summation extends up to year t. Assuming a linear dependency 
on dose, one can divide R(t) by the average dose, /5, in the collective, to 
obtain the cumulative rate per unit dose. This was the procedure in the 
earlier analysis [8]. The approach depends on the implicit assumption, that 
the average dose,/5, in the collective still under observation does not change 
during the follow-up. As seen in the second panel from top in Fig. 2, this 
assumption is largely met, at least in the first 30 years of the follow-up; 
the simplified analysis is, therefore, essentially correct. 
It is nevertheless of interest o consider the more rigorous solution. If 
the average doses, /5i, during the follow-up are not the same, one has - 
again with a linear model - the following relation for the cumulative rate, 
R(t)//5, at unit dose: 
ni 
R(t)//5= ~ N~/5, (2) 
i<t  
This formula has been used to derive the cumulative and the differential 
risks represented in the two lower panels of Fig. 2. The results are nearly 
identical with the ones obtained earlier [8]. 
In spite of its irregularities the temporal distribution in the bottom panel 
of Fig. 2 is in evident general agreement with an assumed log-normal distri- 
bution. This will be substantiated and quantified in the subsequent consider- 
ations. 
First it will, however, be necessary to consider computations not based 
on a linear dose dependency. 
3.2 Computation i terms of a non-linear dose d pendency 
An essential feature of the data - and an implicit condition in the earlier 
analysis by Mays and Spiess [-5, 8] - is the absence of a recognizable correla- 
tion between time to tumor and dose. No systematic decrease of the mean 
time to the tumor with increasing dose is evident from Fig. 1, and no such 
decrease has been identified in computations performed with different age 
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groups [,1]. The apparent lack of dependence of time to the tumor on dose 
and age at exposure has made it possible to analyse the data in terms 
of a model that represents he excess tumor rate as the product of a base-line 
function, to(t), depending merely on time after treatment, and a term, h(D), 
depending on dose: 
r(t, D) = r o (t). h(D) (3) 
The cumulative rate follows the analogous equation: 
R(t, D) = Ro(t ). h(D) (4) 
where R o (t) is the cumulative of r 0 (t). 
These relations correspond to a proportional hazards model. According 
to established statistical terminology, ro(t ) is termed the base-line function. 
However, one must note the difference to another common usage where 
the term base-line function is utilized for the spontaneous, age specific tumor 
rate, and where the variable t refers then to age, and not to time after 
radiation exposure. As stated, spontaneous rates can be disregarded in the 
present analysis, and r 0 (t) is not coupled to the age specific rates. 
The proportional hazards computations can either be performed with 
no analytical expression postulated for the time dependency, i.e. for to(t) 
(or Ro(t)), or they can be performed according to specified models, with 
assumed analytical expressions for the time and dose dependencies. The 
non-parametric analysis is more fundamental in the sense of avoiding possi- 
ble bias of the results due to the assumption of an analytical expression 
for the time dependency. The parametric analysis is, on the other hand, 
less vulnerable to statistical f uctuations in the data, and it has the advantage 
to provide smooth dependencies which are more readily applicable to risk 
estimation, to he computation of probabilities of causation, or to modelling 
in terms of mathematical theories of radiation carcinogenesis. 
The analysis has earlier been performed without an assumed analytical 
expression for ro(t ) (or Ro(t)) but with the familiar linear-quadratic depen- 
dency on dose which is expressed by the equation: 
R (t, D) = R o (t). (D + fl D2) • exp ( - y D). (5) 
The maximum likelihood solution of this model for the entirety of the data 
has provided the following relation for the asymptotic umulative rate, i.e. 
the total risk: 
R (t > 33, D) = 0.0083. (O + 0.23 OZ) • exp( -  0.027 D) (6) 
with the mean skeletal dose, D, in gray. Slight changes in the numerical 
values, compared to the earlier results [-1], are due to the continuation 
of the follow-up till 1987 (see Table 2). 
One may note that he assumed dose relation, whether linear or non- 
linear, has little influence on the resulting base-line function. The temporal 
distribution in Fig. 3 agrees, therefore, closely with that obtained from the 
linear model (Fig. 2, two lower panels). 
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Table 2. Dose parameters from the proportional hazards analyses 
Previous analysis Present analysis 
non-parametric non-parametric parametric 
linear-quadratic (5) linear (2) linear-quadratic (5) linear-quadratic (8) 
t I =0  t t =2 years 
Ro(25 ) =0.0085 Gy -~ Ro(33 ) =0.0185 Ro(33)=0.0083 Gy - t  E=0.0083 E=0.0085 Gy ~ 
/?a =0.2 Gy -1 /? =0 fl =0.23 Gy -1 /?=0.22 /?=0.22 Gy -~ 
=0.025 Gy -~ ~ =0 7 =0.027 GY -~ 7 =0.024 7 =0.025 Gy -1 
a The inverse of fl is the dose where the quadratic term equals the linear term 
0.06 
lO 
0.12. 
DISTRIBUTION OF TIMES 
TO THE TUMOR 
20 30 40 
YEARS AFTER TREATMENT 
Fig. 3. The two base-line functions 
obtained with a proportional hazards 
analysis under the assumption of a 
linear-quadratic dose relation. The 
histogram results from the non- 
parametric analysis, the smooth 
curve from the analysis with a log- 
normal distribution of time to the 
tumor, with q =0 (see (8)) 
However, the result of the non-linear fit implies a substantially reduced 
risk estimate at small doses. The reduced estimate is in essential agreement 
with observations from a current follow up [-12] of patients receiving the 
present day radium-224 therapy with considerably reduced doses. The 
changed risk estimate makes it desirable to perform the proportional hazards 
computations also in terms of a log-normal temporal distribution and to 
obtain, in this way, a comparison with the NIH results [9]. 
4. Proportional hazards analysis in terms of a log-normal distribution 
of times to the tumor 
The proportional hazards model was used in the previous analysis to quan- 
tify the risk due to radium-224. To avoid possible bias, no analytical expres- 
sion was used for the base-line function, ro(t). The disadvantage of the meth- 
od is, that one obtains a discontinuous temporal distribution, as shown 
by the histogram in Fig. 3. For other applications, particularly for the com- 
putations of probabilities of causation, one requires smooth distributions. 
It is then desirable to perform a fully parametric analysis. As emphasized 
by Land [4], the radium-224 induced bone sarcomas hare with the radiation 
induced leukemias the characteristic of wave like temporal distributions 
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which reach a maximum several years after the exposure and become very 
small after a few decades. One speaks of an absolute risk model, since there 
is no assumed linkage between the age specific spontaneous incidence and 
the time dependency of the radiation induced malignancies 3. The similarity 
is particularly close with the radiation induced chronic granulocytic leuke- 
mia; for this leukemia, too, it is assumed that the temporal distribution 
is independent of dose and, of age at exposure. Land [4] has proposed 
to fit such data with a log-normal distribution of times to the tumor: 
l iexp(-(ln('c-_t,)-ln(to))Z ~ 
T(t)-  ] /~a  t~ 2a 2 ] d(ln(z)) (7) 
T(t) is the cumulative distribution of appearance times, t; the notation T(t) 
(rather than Ro (t)) is chosen in conformance with the notation in the NIH- 
tables. T(t) is independent of dose, and normalized to 1. In order to obtain 
the cumulative bone-sarcoma r te, one has to multiply T(t) by the total 
risk, at the specified dose, over the entire expression time. Equation (7) 
contains three parameters, to and a are the two parameters of the log-normal 
distribution, and tl is an assumed minimum latent time, to account for 
a minimum manifestation period for bone sarcomas (or leukemias). 
The analysis in terms of the log-normal distribution has been introduced 
by the NIH-tables committee [-9] and by Land [4] who applied it to the 
leukemias among the atomic bomb survivors, the British ankylosing spondy- 
litis patients treated by x-rays, and to the bone sarcomas in the radium-224 
patients. The NIH panel derived the best fit parameters of the log-normal 
distribution for the bone sarcomas among the radium-224 patients in an 
approach based on reweighted least squares. They referred - as did Mays 
et al. [8] - the calculations merely to the number of patients still under 
observation at any time. As pointed out, this approach is valid for a linear 
model and under the condition that the average skeletal dose of those under 
observation changes little during the follow-up. The calculations were based 
on 898 patients, including those 38 (with 6 bone sarcomas) without known 
dose, who were excluded from the present analysis. 
The time distribution used for the NIH tables is indicated in Fig. 4 
(broken line). This is the derivative of the integral function in (7). The result 
is very close to the time dependency obtained in the proportional hazards 
computations to be described subsequently (solid curve in Figs. 3 and 4). 
The importance of the fitted log-normal distribution for the probability 
of causation tables, and, generally, for quantification ofdose and time depen- 
dencies of radiation induced cancers, justifies that a similar analysis be per- 
formed also in terms of the proportional hazards model which takes into 
account a non-linear dose dependency of the bone sarcomas. Accordingly 
3 For an alternative approach, in which a multiplicative linkage is assumed in analyses of 
both bone sarcoma and leukemia see [4]. In that paper, however, the application to bone 
sarcoma is flawed by a computational error resulting in an erroneously flat expected rate 
at zero dose (Land, personal communication) 
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the computations are performed with the linear-quadratic dose dependency: 
R (t, D) = T(t). E. (D + fi D2), exp (-- 7 D) (8) 
In accordance with the notation in the NIH-tables, E designates the total 
risk, i.e. the asymptotic value of the cumulative rate, when the dose depen- 
dent term equals unity. The difference to the earlier proportional hazards 
analysis is that the log-normal distribution, T(t), takes the place of the 
non-parametric base-line function, Ro (t). 
Excluding negative values of the parameter tl, one obtains the maximum 
likelihood with the parameters to = 10.7 years and o-= 0.52 and with tl =0, 
i.e., with no minimum latent period. This solution is plotted as solid curve 
in Fig. 3 (and in Fig. 4). The absence of a minimum latent period may seem 
to be in contradiction with the fact that induced tumors can appear only 
after a minimal duration required for tumor growth. However, as seen from 
the figures, there is a virtual minimum latent period, because the amplitude 
of the time distribution is very small for times, t, less than about 2 years. 
This is a duration consistent with known cell kinetic parameters. It takes 
30 volume-doubling times for a cancer cell, 10 gm in diameter to enlarge 
to a detectable tumor, 1 cm in diameter. Sequential x-ray measurements 
of tumor size [11] indicate an average volume doubling time of roughly 
one month for human osteosarcomas. Thus the average tumor growth time 
is approximately 30 months or 2.5 years. The shortest ime to bone sarcoma 
diagnosis in the radium-224 patients was 3.5 years (rounded to 4 years). 
Although the maximum likelihood solution with t I = 0 is consistent with 
a practical minimal latent period, it is nevertheless of interest o consider 
the optimal fit with an assumed latent period tl = 2 years which corresponds 
to the observations on tumor growth; the resulting solution is also given 
in Fig. 4 (dashed curve) and its parameters are listed in Tables 2 and 3. 
The two curves are in close agreement, and it is evident that the analysis 
can not decide against either solution. It is also seen that the results agree 
well with those in the NIH tables. The temporal distribution earlier deduced 
is, therefore, confirmed by the present analysis which accounts for the distri- 
bution of skeletal doses and for a non-linear dependency on dose. The close 
agreement is due to the fact that the distribution of mean skeletal doses 
among the patients remains ubstantially unchanged over most of the follow- 
up period (see Fig. 2). One notes, furthermore, that the inclusion of the 
patients with unknown doses has little influence on the results. 
Table 3. Parameters of the log-normal distributions. Pa- 
rameters ~r, t o and t l :  see (7). tmod: most probable time 
to the tumor  (see (9)); tmecl: median time to the tumor 
(see (10)); t-: mean time to the tumor (see (11)) 
Present analysis NIH-parameters  
a = 0.52 0.68 0.69 
to (years)= 10.7 8.5 8.3 
tl (years)= 0 2.0 1.52 
tmoa (years)= 8.2 7.4 6.7 
t moa (years)= 10.7 10.5 9.8 
t (years)= 12.3 12.7 12.1 
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In Fig. 3 the parametric temporal distribution is compared to the earlier- 
non-parametric time dependence, ro(t). Table 2 gives the dose parameters 
for the non-parametric (2) and (5), and for the parametric (8) analyses. As 
is seen from the table, the differences in the derived assumed temporal distri- 
butions, have little influence on the dose parameters. The parametric analysis 
in terms of a linear quadratic dose relation confirms the earlier finding 
of a substantial quadratic term in dose, and of a risk coefficient at low 
doses (linear term) which is, compared to values in the NIH tables, reduced 
by a factor 2. 
The parameters of the temporal distributions obtained from the present 
analysis, with and without assumed minimum latent period, and those in 
the NIH tables are compared in Table 3. One must note that these parame- 
ters refer to the log-normal distribution, so that to is not the mean latent 
period and 0. is not the standard eviation of the latent periods. However 
one can give the relations for the more direct characteristics of the distribu- 
tions, especially the equations for the modal time, tmoa, to the tumor (i.e. 
the most likely time), the median time, treed, and the mean time, t, to the 
tumor: 
tmo a----- t o exp(-- 0.2) + tx (9) 
treed=tO+t1 (10) 
t-=t o exp(0.50-2) + tl (11) 
For completeness, we state also the relations for the moments of the distribu- 
tions of the times to the tumor and for the standard eviation, at (where 
the index t is used to distinguish the quantity from the parameter a in 
the log-normal distribution): 
7n n t = to exp (0.5/,/2 0.2) (12) 
0.t = to ]//exp(0.2)(exp(0- 2) -- 1)) (13) 
5. Conclusions and implications for the radioepidemiological tables 
The risk from radium-224 is - apart from the continued medical application 
- of minor practical importance. It is, nevertheless, of interest in the general 
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context of the analysis of  the dose and time dependencies of radiat ion in- 
duced cancers, especially by e-emitters. The observat ions in the radium-224 
patients have permitted the most  precise determinat ion of  a time dependence 
among all relevant studies. The results have therefore model  character  for 
the formal ism util ized in the Radioepidemio log ica l  Tables. The conclusions 
are closely related also to the formal ism employed for leukemias. 
The present analysis conf irms the tempora l  d istr ibut ion employed in 
the N IH  tables. Var iat ions ascribable to the use of  slightly different data 
sets, different dose-response assumptions,  and different minimal  latent peri- 
ods were minor.  On  the other  hand,  the dose-response model  employed 
in this paper  gives a low-dose risk estimate somewhat  less than half  that  
obta ined under  linearity, and would, if adopted,  yield corresponding ly  
smaller probabi l i ty  of  causat ion values. 
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